[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"egfr-mutation-positive-non-small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:egfr-mutation-positive-non-small-cell-lung-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100617168","phase-1-study-of-nxp900-with-osimertinib-in-subjects-with-advanced-egfr-mutated-non-small-cell-lung-cancer-100617168",false,"NCT07315113","Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer","A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Provide written informed consent.\n2. 18 years old or older.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.\n5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.\n\nExclusion Criteria:\n\n1. Subject's cancer has a known oncogenic driver alteration other than EGFR.\n2. Known EGFR mutations that cause resistance to osimertinib\n3. Known human epidermal growth factor receptor 2 (HER2) overexpression\n4. Any contraindications to treatment with osimertinib","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)",[26,27],"EGFR Mutation Positive Non-small Cell Lung Cancer","EGFR Mutated Non-small Cell Lung Cancer Patients",[29,30,31,32,33,34,35,36],"EGFR","Epidermal growth factor receptor","NSCLC","non-small cell lung cancer","lung cancer","osimertinib","NXP900","EGFR mutation","RECRUITING","2025-12-18",{"date":40,"type":41},"2026-01-02","ACTUAL",{"date":38,"type":41},{"date":44,"type":20},"2027-06",{"name":46,"class":47},"Nuvectis Pharma, Inc.","INDUSTRY",3]